Publications: Nolan, David

Journal Article

Herrmann, S., McKinnon, E., Hyland, N.B., Lalanne, C., Mallal, S., Nolan, D., Chassany, O. and Duracinsky, M. (2013) HIV-related stigma and physical symptoms have a persistent influence on health-related quality of life in Australians with HIV infection. Health and Quality of Life Outcomes, 11 (1).

Nolan, D., Castley, A., Tschochner, M., James, I., Qiu, W., Sayer, D., Christiansen, F.T., Witt, C., Mastaglia, F., Carroll, W. and Kermode, A. (2012) Contributions of vitamin D response elements and HLA promoters to multiple sclerosis risk. Neurology, 79 (6). pp. 538-546.

Achhra, A.C., Amin, J., Hoy, J., Tanuma, J., Sirisanthana, T., Nolan, D., Merati, T. and Giles, M. (2012) Differences in lipid measurements by antiretroviral regimen exposure in cohorts from Asia and Australia. AIDS Research and Treatment, 2012 . pp. 1-9.

Herrmann, S., Wardrop, J., John, M., Gaudieri, S., Lucas, M., Mallal, S. and Nolan, D. (2012) The impact of visa status and Medicare eligibility on people diagnosed with HIV in Western Australia: a qualitative report. Sexual Health, 9 (5). p. 407.

Pfafferott, K., Gaudieri, S., Ulsenheimer, A., James, I., Heeg, M., Nolan, D., John, M., Rauch, A., Mallal, S., Lucas, A.D., Klenerman, P., Diepolder, H.M. and Lucas, M. (2011) Constrained pattern of viral evolution in acute and early HCV infection limits viral plasticity. PLoS ONE, 6 (2). e16797.

Hertz, T., Nolan, D., James, I., John, M., Gaudieri, S., Phillips, E.J., Huang, J.C., Riadi, G., Mallal, S. and Jojic, N. (2011) Mapping the Landscape of Host-Pathogen Coevolution: HLA Class I Binding and Its Relationship with Evolutionary Conservation in Human and Viral Proteins. Journal of Virology, 85 (3). pp. 1310-1321.

John, M., Heckerman, D., James, I., Park, L.P., Carlson, J.M., Chopra, A., Gaudieri, S., Nolan, D., Haas, D.W., Riddler, S.A., Haubrich, R. and Mallal, S. (2010) Adaptive interactions between HLA and HIV-1: highly divergent selection imposed by HLA class I molecules with common supertype motifs. The Journal of Immunology, 184 (8). pp. 4368-4377.

Iwabu, Y., Kinomoto, M., Tatsumi, M., Fujita, H., Shimura, M., Tanaka, Y., Ishizaka, Y., Nolan, D., Mallal, S., Sata, T. and Tokunaga, K. (2010) Differential anti-APOBEC3G activity of HIV-1 Vif proteins derived from different subtypes. Journal of Biological Chemistry, 285 (46). pp. 35350-35358.

Falster, K., Wand, H., Donovan, B., Anderson, J., Nolan, D., Watson, K., Watson, J. and Law, M.G (2010) Hospitalizations in a cohort of HIV patients in Australia, 1999–2007. AIDS, 24 (9). pp. 1329-1339.

Hammond, E.L., McKinnon, E. and Nolan, D. (2010) Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: Prevalence and metabolic consequences. Clinical Infectious Diseases, 51 (5). pp. 591-599.

Herrmann, S.E., McKinnon, E.J., Williams, L.J., John, M., Mallal, S., Lucas, M. and Nolan, D.A. (2010) Use of alcohol, nicotine and other drugs in the Western Australian HIV Cohort study. Sexual Health, 9 (2). pp. 199-201.

McKinnon, E., Morahan, G., Nolan, D. and James, I. (2009) Association of MHC SNP genotype with susceptibility to type 1 diabetes: a modified survival approach. Diabetes, Obesity and Metabolism, 11 (Supp. 1). pp. 92-100.

Rauch, A., James, I., Pfafferott, K., Nolan, D., Klenerman, P., Cheng, W., Mollison, L., McCaughan, G., Shackel, N., Jeffrey, G.P., Baker, R., Freitas, E., Humphreys, I., Furrer, H., Günthard, H.F., Hirschel, B., Mallal, S., John, M., Lucas, M., Barnes, E. and Gaudieri, S. (2009) Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. Hepatology, 50 (4). pp. 1017-1029.

Nolan, D. (2009) HLA-B*5701 screening prior to abacavir prescription: Clinical and laboratory aspects. Critical Reviews in Clinical Laboratory Sciences, 46 (3). pp. 153-165.

Gaudieri, S., Rauch, A., Pfafferott, K., Barnes, E., Cheng, W., McCaughan, G., Shackel, N., Jeffrey, G.P., Mollison, L., Baker, R., Furrer, H., Günthard, H.F., Freitas, E., Humphreys, I., Klenerman, P., Mallal, S., James, I., Roberts, S., Nolan, D. and Lucas, M. (2009) Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy. Hepatology, 49 (4). pp. 1069-1082.

Phillips, E., Nolan, D. and Mallal, S. (2008) The Authors reply - Response to Vandekerckhove et al & Abel et al. New England Journal of Medicine, 358 (23). pp. 2515-2516.

Almeida, C.M., Martin, A.M., Nolan, D., Lucas, A., Cameron, P.U., James, I., Phillips, E. and Mallal, S. (2008) Cytokine profiling in abacavir hypersensitivity patients. Antiviral Therapy, 13 (2). pp. 281-288.

Hammond, E.L., Martin, A., Nolan, D., Metcalf, C. and Mallal, S. (2008) Eruptive haemangioma associated with HIV therapy and mitochondrial pathology. Pathology, 40 (4). pp. 425-429.

Mallal, S., Phillips, E., Carosi, G., Molina, J-M, Workman, C., Tomazic, J., Jagel-Guedes, E., Rugina, S., Kozyrev, O., Cid, J.F., Hay, P., Nolan, D., Hughes, S., Hughes, A., Ryan, S., Fitch, N., Thorborn, D. and Benbow, A. (2008) HLA-B*5701 screening for hypersensitivity to Abacavir. The New England Journal of Medicine, 358 (6). pp. 568-579.

Rauch, A., Nolan, D., Furrer, H., McKinnon, E., John, M., Mallal, S., Gaudieri, S., Günthard, H.F., Schmid, P., Battegay, M., Hirschel, B., Telenti, A., James, I. and Swiss HIV Cohort Study, . (2008) HLA‐Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapy. Clinical Infectious Diseases, 46 (12). pp. 1921-1925.

Chessman, D., Kostenko, L., Lethborg, T., Purcell, A.W., Williamson, N.A., Chen, Z., Kjer-Nielsen, L., Mifsud, N.A., Tait, B.D., Holdsworth, R., Almeida, C.M., Nolan, D., Macdonald, W.A., Archbold, J.K., Kellerher, A.D., Marriott, D., Mallal, S., Bharadwaj, M., Rossjohn, J. and McCluskey, J. (2008) Human leukocyte Antigen Class I-restricted activation of CD8+ T Cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity, 28 (6). pp. 822-832.

Hammond, E.L., McKinnon, E., Mallal, S. and Nolan, D. (2008) Longitudinal evaluation of cardiovascular disease-associated biomarkers in relation to abacavir therapy. AIDS, 22 (18). pp. 2540-2543.

Rauch, A., Gaudieri, S., Evison, J., Nolan, D., Cavassini, M., Weber, R., James, I. and Furrer, H. (2008) Low current and nadir CD4+ T-cell counts are associated with higher hepatitis C virus RNA levels in the Swiss HIV cohort study. Antiviral Therapy, 13 (3). pp. 455-60.

Rauch, A., Nolan, D., Thurnheer, C., Fux, C.A., Cavassini, M., Chave, J-P, Opravil, M., Phillips, E., Mallal, S. and Furrer, H. (2008) Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study. Antiviral Therapy, 13 (8). pp. 1019-1028.

Hammond, E. and Nolan, D. (2007) Adipose tissue inflammation and altered adipokine and cytokine production in antiretroviral therapy-associated lipodystrophy (Review). Current Opinion in HIV and AIDS, 2 (4). pp. 274-281.

Hammond, E., Mamotte, C., Nolan, D. and Mallal, S. (2007) HLA-B*5701 typing: evaluation of an allele-specific polymerase chain reaction melting assay. Tissue Antigens, 70 (1). pp. 58-61.

Nolan, D. (2007) The view from Sydney: 9th International Lipodystrophy Workshop. Nutrition and Metabolic Disorders in HIV Infection, 6 (3). pp. 1161-11643.

Martin, A., Almeida, C.M., Cameron, P.U., Purcell, Anthony W, Nolan, D., James, I., McCluskey, J., Phillips, E.J., Landay, Alan and Mallal, S. (2007) Immune responses to abacavir in antigen-presenting cells from hypersensitive patients. AIDS, 21 (10). pp. 1233-1244.

Lucas, A., Nolan, D. and Mallal, S. (2007) HLA-B*5701 screening for susceptibility to abacavir hypersensitivity. Journal of Antimicrobial Chemotherapy, 59 (4). pp. 591-593.

Hammond, E., Almeida, C.M., Mamotte, C., Nolan, D., Phillips, E.J., Schollaardt, T.A., Gill, M.J., Angel, J.B., Neurath, D., Li, J., Giulivi, T., McIntyre, C., Koultchitski, G., Wong, B., Reis, M., Rachlis, A., Cole, D., Chew, C.B., Neifer, S., Lalonde, R., Roger, M., Jeanneau, A. and Mallal, S. (2007) External quality assessment of HLA-B*5701 reporting: an international multicentre survey. Antiviral Therapy, 12 (7). pp. 1027-1032.

Martin, A., Nolan, D., Almeida, C., Rauch, A. and Mallal, S. (2006) Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench and back again. Pharmacogenomics, 7 (1). pp. 15-23.

Martins, I.J., Hone, E., Foster, J.K., S, S.I., Gnjec, A., Fuller, S.J., Nolan, D., Gandy, S.E. and Martins, R.N. (2006) Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Molecular Psychiatry, 11 (8). pp. 721-736.

Nolan, D., Phillips, E. and Mallal, S. (2006) Efavirenz and CYP2B6 polymorphism: Implications for drug toxicity and resistance. Clinical Infectious Diseases, 42 (3). pp. 408-410.

Nolan, D., Gaudieri, S. and Mallal, S. (2006) Host genetics and viral infections: Immunology taught by viruses, virology taught by the immune system. Current Opinion in Immunology, 18 (4). pp. 413-421.

Pace, C., Keller, J., Nolan, D., James, I., Gaudieri, S., Moore, C. and Mallal, S. (2006) Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. Journal of Virology, 80 (18). pp. 9259-9269.

Rauch, A., Nolan, D., Martin, A., McKinnon, E., Almeida, C. and Mallal, S. (2006) Prospective genetic screening decreases the incidence of Abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clinical Infectious Diseases, 43 (1). pp. 99-102.

Cherry, C.L., Nolan, D., James, I.R., McKinnon, E.J., Mallal, S.A., Gahan, M.E., Lal, L., McArthur, J.C. and Wesselingh, S.L. (2006) Tissue-specific associations between mitochondrial DNA levels and current treatment status in HIV-Infected individuals. JAIDS Journal of Acquired Immune Deficiency Syndromes, 42 (4). pp. 435-440.

Martin, A.M., Krueger, R., Almeida, C.A., Nolan, D., Phillips, E. and Mallal, S. (2006) A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome. Pharmacogenetics and Genomics, 16 (5). pp. 353-357.

Nolan, D., Reiss, P. and Mallal, S. (2005) Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics. Expert Opinion on Drug Safety, 4 (2). pp. 201-218.

Nolan, D. and Mallal, S. (2005) Antiretroviral-therapy-associated lipoatrophy: current status and future directions. Sexual Health, 2 (3). pp. 153-163.

Gaudieri, S., Nolan, D., McKinnon, E., Witt, C.S., Mallal, S. and Christiansen, F.T. (2005) Associations between KIR epitope combinations expressed by HLA-B/-C haplotypes found in an HIV-1 infected study population may influence NK mediated immune responses. Molecular Immunology, 42 (4). pp. 557-560.

Lucas, A.D., Gaudieri, S., Rauch, A., Nolan, D. and Mallal, S. (2005) Cellular tropism of HIV-1 mediated and contrained by coreceptor dependencies. Journal of Viral Entry, 1 (1). pp. 17-27.

Phillips, E.J., Wong, G., Kaul, R., Shahabi, K., Nolan, D., Knowles, S.R., Martin, A.M., Mallal, S. and Shear, N.H. (2005) Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS, 19 (9). pp. 979-981.

Nolan, D. (2005) Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy? Drug Safety, 28 (12). pp. 1069-1074.

Gruters, R.A., Osterhaus, A.D.M.E., Nolan, D., James, I. and Mallal, S. (2005) HIV and smallpox. Science, 308 (5726). 1258b-1259b.

Nolan, D., James, I. and Mallal, S. (2005) HIV/AIDS: HIV: Experiencing the pressures of modern life. Science, 307 (5714). pp. 1422-1424.

Martin, A.M., Nolan, D. and Mallal, S. (2005) HLA-B*5701 typing by sequence-specific amplification: validation and comparison with sequence-based typing. Tissue Antigens, 65 (6). pp. 571-574.

Gaudieri, S., DeSantis, D., McKinnon, E., Moore, C., Nolan, D., Witt, C.S., Mallal, S.A. and Christiansen, F.T. (2005) Killer immunoglobulin-like receptors and HLA act both independently and synergistically to modify HIV disease progression. Genes and Immunity, 6 (8). pp. 683-690.

Martin, A.M., Nolan, D., James, I., Cameron, P., Keller, J., Moore, C., Phillips, E., Christiansen, F.T. and Mallal, S. (2005) Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS, 19 (1). pp. 97-99.

Nolan, D. and Mallal, S. (2004) Complications associated with NRTI therapy: Update on clinical features and possible pathogenic mechanisms. Antiviral Therapy, 9 . pp. 849-863.

Nolan, D., Gaudieri, S., John, M. and Mallal, S. (2004) Impact of host genetics on HIV disease progression and treatment: New conflicts on an ancient battleground. AIDS, 18 (9). pp. 1231-1240.

Martin, A.M., Nolan, D., Gaudieri, S., Phillips, E. and Mallal, S. (2004) Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity. Pharmacogenomics, 5 (6). pp. 643-655.

Martin, A.M., Nolan, D., Gaudieri, S., Almeida, C., James, I., Phillips, E. and Mallal, S. (2004) Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proceedings of the National Academy of Sciences, 101 (12). pp. 4180-4185.

Hammond, E., Nolan, D., James, I., Metcalf, C. and Mallal, S. (2004) Reduction of mitochondrial DNA content and respiratory chain activity occurs in adipocytes within 6-12 months of commencing nucleoside reverse transcriptase inhibitor therapy. AIDS, 18 (5). pp. 815-817.

Nolan, D. and Mallal, S. (2004) The role of nucleoside reverse transcriptase inhibitors in the fat redistribution syndrome. Journal of HIV Therapy, 9 (2). pp. 34-40.

Martin, A.M., Hammond, E., Nolan, D., Pace, C., den Boer, M., Taylor, L., Moore, H., Martinez, O.P., Christiansen, F.T. and Mallal, S. (2003) Accumulation of mitochondrial DNA mutations in Human Immunodeficiency Virus–infected patients treated with Nucleoside-analogue Reverse-transcriptase inhibitors. American Journal of Human Genetics, 72 (3). pp. 549-560.

Hammond, E.L., Sayer, D., Nolan, D., Walker, U.A., de Ronde, A., Montaner, J.S.G., Côté, H.C.F., Gahan, M.E., Cherry, C.L., Wesselingh, S.L., Reiss, P. and Mallal, S. (2003) Assessment of precision and concordance of quantitative mitochondrial DNA assays: A collaborative international quality assurance study. Journal of Clinical Virology, 27 (1). pp. 97-110.

Nolan, D., Hammond, E., James, I., McKinnon, E. and Mallal, S. (2003) Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antiviral Therapy, 8 . pp. 617-626.

Nolan, D., Watts, G.F., Herrmann, S.E., French, M.A., John, M. and Mallal, S. (2003) Endothelial function in HIV-infected patients receiving protease inhibitor therapy: does immune competence affect cardiovascular risk? QJM, 96 (11). pp. 825-832.

Nolan, D., Hammond, E., Martin, A., Taylor, L., Herrmann, S., McKinnon, E., Metcalf, C., Latham, B. and Mallal, S. (2003) Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS, 17 (9). pp. 1329-1338.

Pace, C.S., Martin, A.M., Hammond, E.L., Mamotte, C.D.S., Nolan, D.A. and Mallal, S.A. (2003) Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. Antiviral Therapy, 8 . pp. 323-331.

Nolan, D., Gaudieri, S. and Mallal, S. (2003) Pharmacogenetics: A practical role in predicting antiretroviral drug toxicity? Journal of HIV therapy, 8 (2). pp. 36-41.

John, M., McKinnon, E.J., James, I.R., Nolan, D., Herrmann, S.E., Moore, C.B., White, A.J. and Mallal, S.A. (2003) Randomised, controlled, 48-week study of switching stavudine and/or protease inhibitors to Combavir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. JAIDS Journal of Acquired Immune Deficiency Syndromes, 33 (1). pp. 29-34.

Nolan, D. and Mallal, S. (2003) Thymidine analogue-sparing highly active antiretroviral therapy (HAART). Journal of HIV therapy, 8 (1). pp. 1-5.

Nolan, D., Moore, C., Castley, A., Sayer, D., Marmotte, C., John, M., James, I. and Mallal, S. (2003) Tumour necrosis factor-alpha gene -238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy. AIDS, 17 (1). pp. 121-123.

Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A.M., Moore, C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D., James, I. and Christiansen, F.T. (2002) Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. The Lancet, 359 (9308). pp. 727-732.

Nolan, D., John, M. and Mallal, S. (2001) Antiretoviral therapy and the lipodystrophy syndrome, part 2: Concepts in aetiopathogenesis. Antiviral Therapy, 6 . pp. 145-160.

John, M., Nolan, D. and Mallal, S. (2001) Antiretroviral therapy and the lipodystrophy syndrome. Antiviral Therapy, 6 . pp. 9-20.

John, M., Moore, C.B., James, I.R., Nolan, D., Upton, R.P., McKinnon, E.J. and Mallal, S.A. (2001) Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS, 15 (6). pp. 717-723.

Nolan, D. and Mallal, S. (2001) Effects of sex and race on lipodstrophy pathogenesis. Journal of HIV therapy, 6 (1). pp. 32-36.

Nolan, D. and Mallal, S. (2001) Getting to the HAART of insulin resistance. AIDS, 15 (15). pp. 2037-2041.

Nolan, D., Upton, R., McKinnon, E., John, M., James, I., Adler, B., Roff, G., Vasikaran, S. and Mallal, S. (2001) Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS, 15 (10). pp. 1275-1280.

Nolan, D., Upton, R., James, I., McKinnon, E., John, M. and Mallal, S. (2000) Longitudinal analysis of bone mineral density (BMD) in HIV-infected patients treated with HAART: Changes in BMD correlate with change in subcutaneous fat: With an additional independent effect of indinavir therapy to increase BMD. Antiviral Therapy, 5 (Supp. 5).

Conference Paper

Mallal, S., Moore, C., John, M., James, I., Nolan, D., Sayer, D. and Witt, C. (2000) Characteristic changes in HIV reverse trancriptase sequence at sites encoding known CTL epitopes at a population level. In: XIII International AIDS Conference, 9 - 14 July 2000, Durban, South Africa.

Gizzarelli, L., Hammond, E., Martin, A., Nolan, D. and Mallal, S. (2000) Level of heteroplasmy DNA detection in mtDNA using SSCP and DNA sequencing. In: 12th Annual Conference of the Australian Society for HIV Medicine, 12 - 14 October 2000, Melbourne, Australia.

John, M., Moore, C., James, I., Nolan, D., Upton, R. and Mallal, S. (2000) Predictors of lactic acidemia in the WA HIV cohort. In: Fourth International Cohorts Meeting on HIV Observational Databases, 30 - 31 March 2000, Marbella, Spain.

John, M., Moore, C., James, I., Nolan, D. and Mallal, S. (2000) Predictors of response to antiretroviral therapy in the WA HIV cohort. In: Fourth International Cohorts Meeting on HIV Observational Databases, 30 - 31 March 2000, Marbella, Spain.

White, A.J., John, M., Moore, C., James, I.R., Nolan, D. and Mallal, S.A. (2000) Raised lactate levels are common and may be predictive of subcutaneous fat wasting. In: 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 13 - 15 September 2000, Toronto, Canada.

Conference Item

Herrmann, S., John, M., Wardrop, J. and Nolan, D. (2011) Antiretroviral issues in temporary visa holders in Western Australia: A qualitative report on access, attitude and adherence. In: 23rd Annual Australasian Society for HIV Medicine Conference, 26 - 28 September, Canberra, Australia.

Herrmann, S., John, M., Wardrop, J. and Nolan, D. (2011) Experiences of people on temporary visas who are diagnosed with HIV in Western Australia. In: 23rd Annual Australasian Society for HIV Medicine Conference, 26 - 28 September, Canberra, Australia.

Herrmann, S., Lucas, M., John, M. and Nolan, D. (2011) Implementing medication adherence interventions into HIV clinical care: Implications for current research and other blood borne viruses. In: WA SiREN Research Symposium - Found or Lost in Translation, 6 May, Perth, Western Australia.

Herrmann, S., Williams, L., McKinnon, E. and Nolan, D. (2010) Vulnerable populations: Substance use in the WA HIV Cohort Study. In: 17th Western Australian Drug and Alcohol Symposium, 30 August - 1 September, Fremantle, Western Australia.

Gaudieri, S., Rauch, A., James, I., Pfafferott, K., Baker, R., Cheng, W., McCaughan, G., Shackel, N., Jeffrey, G., Mollinson, L., Mallal, S., Furrer, H., Günthard, H., Hirschel, B., Klenerman, P., Nolan, D., John, M. and Lucas, M. (2009) Co-localisation of hepatitis C virus drug-resistant mutations and immune-driven adaptations: Relevance to therapy outcome. In: 19th Annual Combined Biological Sciences Meeting 2009, 28 August 2009, Perth, Western Australia.

Gaudieri, S., Rauch, A., James, I., Pfafferott, K., Cheng, W., McCaughan, G., Jeffrey, G., Mollison, L., Furrer, H., Günthard, H., Hirschel, B., Klenerman, P., Mallal, S., Nolan, D., John, M. and Lucas, M. (2009) Divergent adaptation of Hepatitis C virus genotypes to HLA-restricted immune pressure: relevance to HCV infection and vaccine design. In: 16th International Symposium on Hepatitis C Virus & Related Viruses, 3 - 7 October 2009, Nice, France.

Nolan, D. and Mallal, S. (2009) EBV and MS: Lessons from hepatitis and HIV. In: 10th Biennial Scientific Conferene on "Progress on MS Research" - MSRA Conference 2009, 15 - 17 October 2009, Sydney, Australia.

Herrmann, S., Duracinsky, M., Lalanne, C., Acquadro, C., Mallal, S. and Nolan, D. (2009) Health-related quality of life in the WA HIV Cohort: 2008. In: 21st Annual Conference of the Australasian Society for HIV Medicine (ASHM), 9 - 11 September, Brisbane, Australia.

Herrmann, S., Williams, L., McKinnon, E. and Nolan, D. (2009) Substance use in the WA HIV Cohort: 2002-2008. In: 21st Annual Conference of the Australasian Society for HIV Medicine (ASHM), 9 - 11 September, Brisbane, Australia.

Duracinsky, M., Herrmann, S., Acquadro, C., Berzins, B., Le Coeur, S., Hyland, N., Fournier, I., McKinnon, E., Nolan, D., Mallal, S. and Chassany, O. (2008) Development of a new health-related quality of life questionnaire specific to HIV/AIDS: an international and cross cultural initiative. In: 20th Annual Australasian Society for HIV Medicine Conference, 17 - 20 September, Perth, Western Australia.

Lo, G., Herrmann, S., Cheng, W., Kontorinis, N., Phillips, E., Nolan, D. and Lucas, M. (2008) Screening for hepatocellular carcinoma (HCC) in hepatitis/HIV co-infection using ultrasound imaging and alfa-feto protein levels. In: 20th Annual Australasian Society for HIV Medicine Conference, 17 - 20 September, Perth, Western Australia.

Herrmann, S., McKinnon, E., John, M., Nolan, D., Martinez, O.P., Phillips, E. and Mallal, S. (2008) Side effects, dosing schedules, pill burden and perceived stress: interaction and influence on medication. In: 20th Annual Australasian Society for HIV Medicine Conference, 17 - 20 September, Perth, Western Australia.

Martin, A., Nolan, D., Rauch, A., Almeida, C., McKinnon, E. and Mallal, S. (2005) Genetic screening for Abacavir hypersensitivity (ABC-HSR) in the Western Australian cohort: Prospective data and novel diagnostic approaches. In: 17th Annual Conference of the Australasian Society for HIV Medicine (ASHM 2005), 24 - 27 August 2005, Hobart, Tasmania.

Martin, A.M., Almeida, C., Nolan, D., Cameron, P., Purcell, A., Chessman, D., McCluskey, J., Phillips, E. and Mallal, S. (2005) Involvement of metabolic and immune responses in the pathogenesis of Abacavir hypersensitivity reaction. In: 17th Annual Conference of the Australasian Society for HIV Medicine (ASHM 2005), 24 - 27 August 2005, Hobart, Tasmania.

Nolan, R., Martin, A.M., Nolan, D., Gaudieri, S., Almeida, C., Carvalho, F., Witt, C., Sayer, D., Herrmann, S., Christiansen, F.T. and Mallal, S. (2003) Abacavir Hypersensitivity Syndrome: Clarifying genetic associations by including the presence of an abacavir specific immune response in diagnostic criteria. In: 15th Annual Conference of the Australian Society for HIV Medicine, 22 - 25 October, Cairns, Australia.

Martin, A., Nolan, D., Gaudieri, S., Almeida, C., Carvalho, F., Witt, C., Sayer, D., Nolan, R., Herrmann, S., Christiansen, F. and Mallal, S. (2003) Updated experience of abacavir hypersensitivity genetic testing within the major histocompatibility complex (MHC): addressing diagnostic precision and predictive value. In: 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 8 - 11 July, Paris, France.

Nolan, D., Mallal, S. and John, M. (2000) Developing tools for investigation of mitochondrial toxicity in the clinical setting. In: Forum for Collaborative HIV Research: Mitochondrial Toxicity and HIV Disease Meeting, 5 - 6 June 2000, Washington, DC.

Mallal, S., Nolan, D., John, M., Chong, D., Metcalf, C. and Latham, B. (2000) Light and electron microscopy findings in subcutaneous fat antiretroviral treated and HIV-infected patients. In: XIII International AIDS Conference, 9 - 14 July 2000, Durban, South Africa.

Nolan, D., Upton, R., James, I., McKinnon, E., John, M. and Mallal, S. (2000) Longitudinal analysis of Bone Mineral Density (BMD) in HIV-infected patients treated with HAART: Changes in BMD correlate with change in subcutaneous fat; with an additional independent effect of indinavir therapy to increase BMD. In: 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 13 - 15 September 2000, Toronto, Canada.